- Oral presentation
- Open Access
Left ventricular mass by cardiac magnetic resonance imaging and adverse cardiovascular outcomes in patients treated with anthracycline-based chemotherapy
© Neilan et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Powerful Predictor
- Adverse Outcome
- Cardiac Magnetic Resonance
- Late Gadolinium Enhancement
LV mass by CMR is a powerful predictor of adverse cardiovascular outcomes in patients treated with anthracyclines.
Late gadolinium enhancement (LGE) is a predictor of adverse outcomes in patients. However, limited data exist on the role of LGE, the characteristic CMR findings, and the prognostic variables in patients who develop a cardiomyopathy after treatment with anthracyclines.
LGE-CMR imaging was performed in patients with stage B and C heart failure after anthracycline-based chemotherapy. We assessed the association between CMR, EKG, echocardiographic, serum, and clinical variables with adverse outcomes (cardiovascular death and admission for heart failure).
Residual LV-mass measured by CMR is a powerful predictor of subsequent adverse cardiovascular events in patients with anthracycline-induced cardiotoxicity.
Dr. Neilan is supported by an NIH T32 Training Grant (T32HL09430101A1).
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.